Phase 1b data on Lu AF28996, an investigational treatment for people with advanced Parkinson’s disease, to be presented at ...
In 2020, Ashley Harms, Ph.D., and University of Alabama at Birmingham colleagues published an Acta Neuropathologica study that used a mouse model to show that the alpha-synuclein pathology from ...
Alterity Therapeutics has appointed internationally recognised expert in neurodegenerative diseases Daniel O Claassen as ...
A study found brain atrophy progresses more slowly with age in RRMS, highlighting the need to factor age into MS clinical ...
A study questioned the use of brain volume loss as a clinical trial endpoint in PPMS after finding a weak link to disability ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results